Sana Biotechnology Inc (SANA) - Total Assets
Based on the latest financial reports, Sana Biotechnology Inc (SANA) holds total assets worth $431.52 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sana Biotechnology Inc - Total Assets Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. Also see Sana Biotechnology Inc market cap and net worth for the company's overall valuation and market capitalisation.
Sana Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Sana Biotechnology Inc's total assets of $431.52 Million consist of 35.7% current assets and 64.3% non-current assets. Review Sana Biotechnology Inc balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $59.20 Million | 14.2% |
| Goodwill | $140.63 Million | 33.7% |
Asset Composition Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SANA stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sana Biotechnology Inc's current assets represent 35.7% of total assets in 2025, a decrease from 94.9% in 2018.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2025, down from 89.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 33.7% of total assets.
Sana Biotechnology Inc Competitors by Total Assets
Key competitors of Sana Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Sana Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 2.47 | 6.66 |
| Quick Ratio | 1.38 | 2.47 | 6.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $46.88 Million | $49.06 Million | $520.84 Million |
Sana Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Sana Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.68 |
| Latest Market Cap to Assets Ratio | 2.27 |
| Asset Growth Rate (YoY) | -16.8% |
| Total Assets | $416.89 Million |
| Market Capitalization | $945.98 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sana Biotechnology Inc's assets at a significant premium (2.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sana Biotechnology Inc's assets decreased by 16.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sana Biotechnology Inc (2018–2025)
The table below shows the annual total assets of Sana Biotechnology Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $416.89 Million | -16.79% |
| 2024-12-31 | $501.02 Million | -11.37% |
| 2023-12-31 | $565.30 Million | -31.29% |
| 2022-12-31 | $822.72 Million | -27.15% |
| 2021-12-31 | $1.13 Billion | +54.65% |
| 2020-12-31 | $730.30 Million | +75.89% |
| 2019-12-31 | $415.19 Million | +1109.31% |
| 2018-12-31 | $34.33 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more